董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Bazemore | 男 | Director | 57 | 35.69万美元 | 44.19 | 2025-12-31 |
| Merdad Parsey | 男 | Director | 62 | 50.33万美元 | 5.25 | 2025-12-31 |
| Muna Bhanji | 女 | Director | 62 | 35.69万美元 | 41.93 | 2025-12-31 |
| Onaiza Cadoret Manier | 女 | Director | 61 | 35.44万美元 | 48.94 | 2025-12-31 |
| William Bertrand, Jr. | 男 | Director | 60 | 36.94万美元 | 68.10 | 2025-12-31 |
| Richard Rodgers | 男 | Director | 59 | 37.69万美元 | 70.39 | 2025-12-31 |
| Michael Raab | 男 | Director,President and Chief Executive Officer | 60 | 779.62万美元 | 527.61 | 2025-12-31 |
| David Mott | 男 | Chairperson | 59 | 41.19万美元 | 359.32 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Laura Williams | 女 | Chief Medical Officer and Chief Patient Officer | 62 | 282.74万美元 | 未持股 | 2025-12-31 |
| Sue Hohenleitner | 女 | Chief Financial Officer | 55 | 343.74万美元 | 1.94 | 2025-12-31 |
| Mike Kelliher | 男 | Executive Vice President, Corporate Development and Strategy | 48 | 未披露 | 未持股 | 2025-12-31 |
| Eric Foster | 男 | Chief Commercial Officer | 50 | 未披露 | 未持股 | 2025-12-31 |
| Michael Raab | 男 | Director,President and Chief Executive Officer | 60 | 779.62万美元 | 527.61 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Robert Bazemore
-
Robert Bazemore，他于2014年9月加入Synageva公司，担任首席运营官，负责公司的全球商业、市场准入和医疗事务运营。他拥有超过22年的生物制药经验，并于最后12年任职Johnson & Johnson公司，担任多种职务，包括Ethicon的新增长平台的副总裁、Janssen Biotech公司（从属于the Janssen Pharmaceutical Companies of Johnson & Johnson）的总裁。他曾担任Janssen Biotech公司的总裁，负责创立Janssen公司的美国肿瘤免疫学和业务，获得超过70亿美元的年收入。他曾担任Janssen Biotech公司的总裁，负责美国肿瘤免疫学业务的增长和多样化，包括主导品牌，如Remicadeinfliximab、Procrit（重组人红细胞生成素）、Simponi（golimumab）、Stelara（ustekinumab）、Zytiga（abiraterone）、Imbruvica（ibrutinib）等。除了他的这些成就，他也曾担任业务开发的关键职务，包括Johnson & Johnson公司于2009年收购Cougar Biotechnology公司，以及Johnson & Johnson公司于2011年与Pharmacyclics公司建立合作关系。他的职业生涯始于2002年任职Johnson & Johnson，并担任多种高级商业职务，并领导全球免疫组合策略和多个推出的新产品和适应症。任职Johnson & Johnson公司期间，他也曾担任Centocor Ortho Biotech公司的负责营销和销售的副总裁，以及负责全球战略营销的全球副总裁。加入Johnson & Johnson公司之前，他曾任职Merck & Co.11年，担任全球营销、呼吸道特许经营企业集团的多种医疗事务、销售和营销职务，并不断被提拔，也曾担任推出美国Singulair（孟鲁司特）的营销团队成员。他持有Georgia大学的生物化学学士学位。
Robert Bazemore has served as a member of Akari Therapeutics, Plc's board of directors since September 2024. Mr. Bazemore has spent over 30 years on the development and commercialization of novel medicines. From 2015 to 2021, Mr. Bazemore served as the President, Chief Executive Officer and member of the Board of Directors of Epizyme, Inc., developing and launching TAZVERIK for patients with Follicular Lymphoma and Sarcoma while building on the company's pipeline of promising epigenetic candidates in oncology. Prior to that, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp., where he established the company's global commercial and medical organization to support the first product launch, helping lead the broader transition to a sustainable commercial enterprise through the company's acquisition by Alexion Pharmaceuticals, Inc. Mr. Bazemore served in increasing levels of responsibility at Johnson & Johnson including Vice President of Centocor Ortho Biotech Sales & Marketing from 2008 to 2010 and President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the US launches of the oncology therapies ZYTIGA and IBRUVICA . He was also Vice President of Global Surgery at Ethicon. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co. Inc., where he served in a variety of roles in medical affairs, sales and marketing, including supporting the launch of SINGULAIR in the U.S. Mr. Bazemore previously served on the board of Neon Therapeutics prior to its acquisition by BioNTech and served as Board Chairman for Pennsylvania BIO. Mr. Bazemore received a B.S. in Biochemistry from the University of Georgia. - Robert Bazemore，他于2014年9月加入Synageva公司，担任首席运营官，负责公司的全球商业、市场准入和医疗事务运营。他拥有超过22年的生物制药经验，并于最后12年任职Johnson & Johnson公司，担任多种职务，包括Ethicon的新增长平台的副总裁、Janssen Biotech公司（从属于the Janssen Pharmaceutical Companies of Johnson & Johnson）的总裁。他曾担任Janssen Biotech公司的总裁，负责创立Janssen公司的美国肿瘤免疫学和业务，获得超过70亿美元的年收入。他曾担任Janssen Biotech公司的总裁，负责美国肿瘤免疫学业务的增长和多样化，包括主导品牌，如Remicadeinfliximab、Procrit（重组人红细胞生成素）、Simponi（golimumab）、Stelara（ustekinumab）、Zytiga（abiraterone）、Imbruvica（ibrutinib）等。除了他的这些成就，他也曾担任业务开发的关键职务，包括Johnson & Johnson公司于2009年收购Cougar Biotechnology公司，以及Johnson & Johnson公司于2011年与Pharmacyclics公司建立合作关系。他的职业生涯始于2002年任职Johnson & Johnson，并担任多种高级商业职务，并领导全球免疫组合策略和多个推出的新产品和适应症。任职Johnson & Johnson公司期间，他也曾担任Centocor Ortho Biotech公司的负责营销和销售的副总裁，以及负责全球战略营销的全球副总裁。加入Johnson & Johnson公司之前，他曾任职Merck & Co.11年，担任全球营销、呼吸道特许经营企业集团的多种医疗事务、销售和营销职务，并不断被提拔，也曾担任推出美国Singulair（孟鲁司特）的营销团队成员。他持有Georgia大学的生物化学学士学位。
- Robert Bazemore has served as a member of Akari Therapeutics, Plc's board of directors since September 2024. Mr. Bazemore has spent over 30 years on the development and commercialization of novel medicines. From 2015 to 2021, Mr. Bazemore served as the President, Chief Executive Officer and member of the Board of Directors of Epizyme, Inc., developing and launching TAZVERIK for patients with Follicular Lymphoma and Sarcoma while building on the company's pipeline of promising epigenetic candidates in oncology. Prior to that, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp., where he established the company's global commercial and medical organization to support the first product launch, helping lead the broader transition to a sustainable commercial enterprise through the company's acquisition by Alexion Pharmaceuticals, Inc. Mr. Bazemore served in increasing levels of responsibility at Johnson & Johnson including Vice President of Centocor Ortho Biotech Sales & Marketing from 2008 to 2010 and President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the US launches of the oncology therapies ZYTIGA and IBRUVICA . He was also Vice President of Global Surgery at Ethicon. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co. Inc., where he served in a variety of roles in medical affairs, sales and marketing, including supporting the launch of SINGULAIR in the U.S. Mr. Bazemore previously served on the board of Neon Therapeutics prior to its acquisition by BioNTech and served as Board Chairman for Pennsylvania BIO. Mr. Bazemore received a B.S. in Biochemistry from the University of Georgia.
- Merdad Parsey
-
Merdad Parsey，自2010年9月起担任Sagimet Biosciences公司董事会成员。2010年9月至2015年10月，帕西博士担任Sagimet Biosciences Inc.首席执行官。自2019年11月起，帕西博士担任吉利德科学公司执行副总裁兼首席医疗官。此前，帕西博士于2006年加入基因泰克公司，最初领导呼吸科，随后于2008年监督免疫学、组织生长和修复产品的早期临床开发。2015年10月至2019年11月，帕西博士在基因泰克担任早期临床开发高级副总裁。帕西博士在马里兰大学获得微生物学和免疫学学士学位，在马里兰大学巴尔的摩分校获得免疫学博士和医学博士学位。他在斯坦福大学完成了内科住院医师实习，并在科罗拉多大学完成了肺病和重症监护奖学金。他曾任纽约大学医学院医学助理教授和重症医学主任，并曾在默克制药公司、再生元制药公司和Sunovion制药公司（fka Sepracor，Inc.）担任临床开发职务。Parsey博士自2020年7月起担任Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS）董事会成员。
Merdad Parsey,has served as a member of Sagimet Biosciences Inc. board of directors since September 2010. From September 2010 to October 2015, Dr. Parsey served as chief executive officer of Sagimet Biosciences Inc. Since November 2019, Dr. Parsey has served as executive vice president and chief medical officer at Gilead Sciences, Inc. Previously, Dr. Parsey joined Genentech, Inc. in 2006 initially leading the respiratory group and subsequently overseeing early clinical development for the immunology, tissue growth and repair portfolio in 2008. From October 2015 to November 2019, Dr. Parsey served as senior vice president of early clinical development at Genentech, Inc. Dr. Parsey received his B.S. in microbiology and immunology at the University of Maryland, his M.D. and Ph.D. in immunology at the University of Maryland at Baltimore. He completed his internal medicine residency at Stanford University and his pulmonary and critical care fellowship at the University of Colorado. He was assistant professor of medicine and director of critical care medicine at the NYU School of Medicine and has been in clinical development roles at Merck & Co., Inc., Regeneron Pharmaceuticals, Inc. and Sunovion Pharmaceuticals, Inc. (fka Sepracor, Inc.). Dr. Parsey has served on the board of directors of Arcus Biosciences, Inc. (NYSE: RCUS) since July 2020. - Merdad Parsey，自2010年9月起担任Sagimet Biosciences公司董事会成员。2010年9月至2015年10月，帕西博士担任Sagimet Biosciences Inc.首席执行官。自2019年11月起，帕西博士担任吉利德科学公司执行副总裁兼首席医疗官。此前，帕西博士于2006年加入基因泰克公司，最初领导呼吸科，随后于2008年监督免疫学、组织生长和修复产品的早期临床开发。2015年10月至2019年11月，帕西博士在基因泰克担任早期临床开发高级副总裁。帕西博士在马里兰大学获得微生物学和免疫学学士学位，在马里兰大学巴尔的摩分校获得免疫学博士和医学博士学位。他在斯坦福大学完成了内科住院医师实习，并在科罗拉多大学完成了肺病和重症监护奖学金。他曾任纽约大学医学院医学助理教授和重症医学主任，并曾在默克制药公司、再生元制药公司和Sunovion制药公司（fka Sepracor，Inc.）担任临床开发职务。Parsey博士自2020年7月起担任Arcus Biosciences, Inc.（纽约证券交易所代码：RCUS）董事会成员。
- Merdad Parsey,has served as a member of Sagimet Biosciences Inc. board of directors since September 2010. From September 2010 to October 2015, Dr. Parsey served as chief executive officer of Sagimet Biosciences Inc. Since November 2019, Dr. Parsey has served as executive vice president and chief medical officer at Gilead Sciences, Inc. Previously, Dr. Parsey joined Genentech, Inc. in 2006 initially leading the respiratory group and subsequently overseeing early clinical development for the immunology, tissue growth and repair portfolio in 2008. From October 2015 to November 2019, Dr. Parsey served as senior vice president of early clinical development at Genentech, Inc. Dr. Parsey received his B.S. in microbiology and immunology at the University of Maryland, his M.D. and Ph.D. in immunology at the University of Maryland at Baltimore. He completed his internal medicine residency at Stanford University and his pulmonary and critical care fellowship at the University of Colorado. He was assistant professor of medicine and director of critical care medicine at the NYU School of Medicine and has been in clinical development roles at Merck & Co., Inc., Regeneron Pharmaceuticals, Inc. and Sunovion Pharmaceuticals, Inc. (fka Sepracor, Inc.). Dr. Parsey has served on the board of directors of Arcus Biosciences, Inc. (NYSE: RCUS) since July 2020.
- Muna Bhanji
-
Muna Bhanji，自2022年4月起担任Intellia Therapeutics，Inc.董事会成员。Bhanji女士是TIBA Global Access，LLC的创始人和负责人，该公司是一家自2021年1月起服务于生物制药行业的商业化和市场准入战略咨询公司。Bhanji女士此前曾在默克制药公司（“默沙东”）担任越来越多的职责，包括在美国和全球商业组织担任多个高级战略领导和运营职务，每年推动超过400 + 10亿美元的广泛药物和疫苗组合的增长。最近，Bhanji女士于2010年至2020年12月期间担任默沙东在世界各地的产品的全球市场准入和政策高级副总裁，负责为患者提供付款人报销和准入，并于2014年至2017年期间担任医院和专科特许经营高级副总裁。此外，Bhanji女士还担任默沙东全球肿瘤学和全球医院及专科商业特许经营高级副总裁。她目前在Cytokinetics，Inc.，Veracyte，Inc.和Ardelyx, Inc.的董事会任职。她还在Corus International的董事会任职。Corus International是一个由信仰组织组成的合奏，致力于世界上服务最欠缺的地区的扶贫和医疗保健的交叉领域。Bhanji女士获得了罗格斯药学院的药学学士学位和圣约瑟夫大学的工商管理硕士学位。
Muna Bhanji,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2022. Ms. Bhanji is the founder and principal of TIBA Global Access, LLC, a commercialization and market access strategy consultancy serving the biopharmaceutical industry since January 2021. Ms. Bhanji previously served in roles of increasing responsibility at Merck & Co., Inc. ("Merck"), including a number of senior strategic leadership and operating roles within the U.S. and global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, Ms. Bhanji served as the senior vice president, global market access & policy with responsibility for enabling payer reimbursement and access for patients, for Merck's products around the world from 2010 through December 2020 and as senior vice president, hospital & specialty franchises from 2014 until 2017. In addition, Ms. Bhanji served as senior vice president for global oncology and global hospital and specialty commercial franchises for Merck. She currently serves on the board of directors of Cytokinetics, Inc., Veracyte, Inc. and Ardelyx, Inc. She also serves on the board of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. Ms. Bhanji earned her B.Sc. in Pharmacy from Rutgers School of Pharmacy and an M.B.A. from St. Joseph's University. - Muna Bhanji，自2022年4月起担任Intellia Therapeutics，Inc.董事会成员。Bhanji女士是TIBA Global Access，LLC的创始人和负责人，该公司是一家自2021年1月起服务于生物制药行业的商业化和市场准入战略咨询公司。Bhanji女士此前曾在默克制药公司（“默沙东”）担任越来越多的职责，包括在美国和全球商业组织担任多个高级战略领导和运营职务，每年推动超过400 + 10亿美元的广泛药物和疫苗组合的增长。最近，Bhanji女士于2010年至2020年12月期间担任默沙东在世界各地的产品的全球市场准入和政策高级副总裁，负责为患者提供付款人报销和准入，并于2014年至2017年期间担任医院和专科特许经营高级副总裁。此外，Bhanji女士还担任默沙东全球肿瘤学和全球医院及专科商业特许经营高级副总裁。她目前在Cytokinetics，Inc.，Veracyte，Inc.和Ardelyx, Inc.的董事会任职。她还在Corus International的董事会任职。Corus International是一个由信仰组织组成的合奏，致力于世界上服务最欠缺的地区的扶贫和医疗保健的交叉领域。Bhanji女士获得了罗格斯药学院的药学学士学位和圣约瑟夫大学的工商管理硕士学位。
- Muna Bhanji,has served as a member of Intellia Therapeutics, Inc. board of directors since April 2022. Ms. Bhanji is the founder and principal of TIBA Global Access, LLC, a commercialization and market access strategy consultancy serving the biopharmaceutical industry since January 2021. Ms. Bhanji previously served in roles of increasing responsibility at Merck & Co., Inc. ("Merck"), including a number of senior strategic leadership and operating roles within the U.S. and global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, Ms. Bhanji served as the senior vice president, global market access & policy with responsibility for enabling payer reimbursement and access for patients, for Merck's products around the world from 2010 through December 2020 and as senior vice president, hospital & specialty franchises from 2014 until 2017. In addition, Ms. Bhanji served as senior vice president for global oncology and global hospital and specialty commercial franchises for Merck. She currently serves on the board of directors of Cytokinetics, Inc., Veracyte, Inc. and Ardelyx, Inc. She also serves on the board of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. Ms. Bhanji earned her B.Sc. in Pharmacy from Rutgers School of Pharmacy and an M.B.A. from St. Joseph's University.
- Onaiza Cadoret Manier
-
Onaiza Cadoret Manier，自2020年3月起担任董事会成员。Cadoret-Manier女士自2024年3月起担任生物技术公司Yemaya Bio的首席执行官、总裁和董事会成员。2022年3月至2024年3月，Cadoret-Manier女士在伊奥尼斯制药（纳斯达克：IONS）担任首席全球产品战略和运营官；2020年1月至2022年3月，Cadoret-Manier女士在伊奥尼斯制药担任首席企业发展和商务官。在此之前，Cadoret-Manier女士于2018年6月至2019年6月担任早期检测基因组学公司Grail Biosciences的首席商务官。在加入Grail之前，从2011年4月到2018年6月，她在生物制药公司Genentech担任呼吸系统特许经营副总裁。Cadoret-Manier女士还担任过多个高级管理职位，负责监督基因泰克、辉瑞和Amylin Pharmaceuticals众多疾病领域的公司战略、联盟以及营销和销售。Cadoret-Manier女士在Ventyx Biosciences（纳斯达克：VTYX）的董事会任职。她拥有芝加哥大学的工商管理硕士学位和纽约市立大学皇后学院的经济学和会计学学士学位。
Onaiza Cadoret Manier,has served on board of directors since March 2020. Ms. Cadoret-Manier has served as the Chief Executive Officer, President and Board Member of Yemaya Bio, a biotechnology company, since March 2024. From March 2022 to March 2024, Ms. Cadoret-Manier served as Chief Global Product Strategy and Operations Officer at Ionis Pharmaceuticals (Nasdaq: IONS), and from January 2020 to March 2022, Ms. Cadoret-Manier served as Chief Corporate Development and Commercial Officer at Ionis Pharmaceuticals. Prior to that, Ms. Cadoret-Manier was the Chief Commercial Officer for Grail Biosciences, an early detection genomics company, from June 2018 until June 2019. Prior to Grail, from April 2011 until June 2018, she was Vice President of the Respiratory Franchise at Genentech, a biopharmaceutical company. Ms. Cadoret-Manier also has held multiple senior management positions overseeing corporate strategy, alliances, and marketing and sales for numerous disease areas for Genentech, Pfizer and Amylin Pharmaceuticals. Ms. Cadoret-Manier serves on the board of directors of Ventyx Biosciences (Nasdaq: VTYX). She has an M.B.A. from the University of Chicago and a bachelor's degree in economics and accounting from City University of New York Queens College. - Onaiza Cadoret Manier，自2020年3月起担任董事会成员。Cadoret-Manier女士自2024年3月起担任生物技术公司Yemaya Bio的首席执行官、总裁和董事会成员。2022年3月至2024年3月，Cadoret-Manier女士在伊奥尼斯制药（纳斯达克：IONS）担任首席全球产品战略和运营官；2020年1月至2022年3月，Cadoret-Manier女士在伊奥尼斯制药担任首席企业发展和商务官。在此之前，Cadoret-Manier女士于2018年6月至2019年6月担任早期检测基因组学公司Grail Biosciences的首席商务官。在加入Grail之前，从2011年4月到2018年6月，她在生物制药公司Genentech担任呼吸系统特许经营副总裁。Cadoret-Manier女士还担任过多个高级管理职位，负责监督基因泰克、辉瑞和Amylin Pharmaceuticals众多疾病领域的公司战略、联盟以及营销和销售。Cadoret-Manier女士在Ventyx Biosciences（纳斯达克：VTYX）的董事会任职。她拥有芝加哥大学的工商管理硕士学位和纽约市立大学皇后学院的经济学和会计学学士学位。
- Onaiza Cadoret Manier,has served on board of directors since March 2020. Ms. Cadoret-Manier has served as the Chief Executive Officer, President and Board Member of Yemaya Bio, a biotechnology company, since March 2024. From March 2022 to March 2024, Ms. Cadoret-Manier served as Chief Global Product Strategy and Operations Officer at Ionis Pharmaceuticals (Nasdaq: IONS), and from January 2020 to March 2022, Ms. Cadoret-Manier served as Chief Corporate Development and Commercial Officer at Ionis Pharmaceuticals. Prior to that, Ms. Cadoret-Manier was the Chief Commercial Officer for Grail Biosciences, an early detection genomics company, from June 2018 until June 2019. Prior to Grail, from April 2011 until June 2018, she was Vice President of the Respiratory Franchise at Genentech, a biopharmaceutical company. Ms. Cadoret-Manier also has held multiple senior management positions overseeing corporate strategy, alliances, and marketing and sales for numerous disease areas for Genentech, Pfizer and Amylin Pharmaceuticals. Ms. Cadoret-Manier serves on the board of directors of Ventyx Biosciences (Nasdaq: VTYX). She has an M.B.A. from the University of Chicago and a bachelor's degree in economics and accounting from City University of New York Queens College.
- William Bertrand, Jr.
-
William Bertrand, Jr.，他被任命为代理首席运营官。他曾一直担任公司的高级法律副总裁、法律顾问、公司秘书（2013年7月以来）。加入Salix公司之前，他曾任职MedImmune公司（被 AstraZeneca AB收购）12年。他也曾多次任职MedImmune公司，负责合法、合规、业务发展，其中包括MedImmune Ventures公司（全资风险基金）、信息技术、公司事务（内部和外部通信）、政府关系和监管事务。加入MedImmune公司之前，他曾担任Pharmacia & Upjohn公司的多种法律职务，并不断被提拔，始于产品诉讼，并进入全球商业和产品支持。他也一直担任律师事务所的合伙人，也曾任职于多个董事会。他持有Wisconsin大学-Madison Law School的法学博士学位（以优异成绩获得），以及Wayne State大学的高级荣誉生物学学士学位。
William Bertrand, Jr.,has served on board of directors since October 2015. Mr. Bertrand has served as the Chief Operating Officer at Adaptimmune Therapeutics Plc (Nasdaq: ADAP) since March 2017. From October 2015 to September 2016, Mr. Bertrand served as the Executive Vice President, General Counsel of Infinity Pharmaceuticals, Inc. (Nasdaq: INFI). From July 2013 to August 2015, Mr. Bertrand held a variety of positions with Salix Pharmaceuticals, Ltd., a biopharmaceutical company, including Senior Vice President, General Counsel, Acting Chief Operating Officer, and most recently, General Manager of Salix Pharmaceuticals following its acquisition by Valeant Pharmaceuticals International (NYSE: VRX) in April 2015. Prior to that, Mr. Bertrand completed a 12-year career at Medimmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc (NYSE: AZN), serving in numerous roles of increasing responsibility, including as Executive Vice President and General Counsel from 2008 to 2013. Mr. Bertrand received his B.S. in Biology from Wayne State University and his J.D. from the University of Wisconsin-Madison. - William Bertrand, Jr.，他被任命为代理首席运营官。他曾一直担任公司的高级法律副总裁、法律顾问、公司秘书（2013年7月以来）。加入Salix公司之前，他曾任职MedImmune公司（被 AstraZeneca AB收购）12年。他也曾多次任职MedImmune公司，负责合法、合规、业务发展，其中包括MedImmune Ventures公司（全资风险基金）、信息技术、公司事务（内部和外部通信）、政府关系和监管事务。加入MedImmune公司之前，他曾担任Pharmacia & Upjohn公司的多种法律职务，并不断被提拔，始于产品诉讼，并进入全球商业和产品支持。他也一直担任律师事务所的合伙人，也曾任职于多个董事会。他持有Wisconsin大学-Madison Law School的法学博士学位（以优异成绩获得），以及Wayne State大学的高级荣誉生物学学士学位。
- William Bertrand, Jr.,has served on board of directors since October 2015. Mr. Bertrand has served as the Chief Operating Officer at Adaptimmune Therapeutics Plc (Nasdaq: ADAP) since March 2017. From October 2015 to September 2016, Mr. Bertrand served as the Executive Vice President, General Counsel of Infinity Pharmaceuticals, Inc. (Nasdaq: INFI). From July 2013 to August 2015, Mr. Bertrand held a variety of positions with Salix Pharmaceuticals, Ltd., a biopharmaceutical company, including Senior Vice President, General Counsel, Acting Chief Operating Officer, and most recently, General Manager of Salix Pharmaceuticals following its acquisition by Valeant Pharmaceuticals International (NYSE: VRX) in April 2015. Prior to that, Mr. Bertrand completed a 12-year career at Medimmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc (NYSE: AZN), serving in numerous roles of increasing responsibility, including as Executive Vice President and General Counsel from 2008 to 2013. Mr. Bertrand received his B.S. in Biology from Wayne State University and his J.D. from the University of Wisconsin-Madison.
- Richard Rodgers
-
Richard Rodgers自2014年12月起担任董事。除了在Rexahn的董事会席位外，罗杰斯先生目前还在Ardelyx，Inc.和3-V Biosciences，Inc.的董事会任职。罗杰斯先生此前曾在2010年3月至2013年8月期间担任他与人共同创立的专注于肿瘤学的生物制药公司TESARO的执行副总裁、首席财务官、秘书和财务主管。曾于2009年6月至2010年2月在Abraxis BioScience担任首席财务官，该公司随后被Celgene收购。在此之前，Rodgers先生曾在2004年至2008年1月被卫材收购之前担任MGI制药公司的高级副总裁、财务总监兼首席会计官。他曾在多家私营和上市公司担任财务和会计职务，包括Arthur Anderson。Rodgers先生获得了圣克劳德州立大学的财务会计学士学位和明尼苏达大学卡尔森商学院的金融MBA学位。
Richard Rodgers has served as a director since December 2014. In addition to his board seat with Rexahn, Mr. Rodgers currently serves on the Board of Directors of Ardelyx, Inc. and 3-V Biosciences, Inc. Mr. Rodgers was previously Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, an oncology-focused biopharmaceutical company that he co-founded, from March 2010 until August 2013. He served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience, which was subsequently acquired by Celgene. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, from 2004 until its acquisition by Eisai in January 2008. He has held finance and accounting positions at several private and public companies, including Arthur Anderson. Mr. Rodgers received a B.S. in Financial Accounting from St. Cloud State University and his MBA in Finance from the University of Minnesota, Carlson School of Business. - Richard Rodgers自2014年12月起担任董事。除了在Rexahn的董事会席位外，罗杰斯先生目前还在Ardelyx，Inc.和3-V Biosciences，Inc.的董事会任职。罗杰斯先生此前曾在2010年3月至2013年8月期间担任他与人共同创立的专注于肿瘤学的生物制药公司TESARO的执行副总裁、首席财务官、秘书和财务主管。曾于2009年6月至2010年2月在Abraxis BioScience担任首席财务官，该公司随后被Celgene收购。在此之前，Rodgers先生曾在2004年至2008年1月被卫材收购之前担任MGI制药公司的高级副总裁、财务总监兼首席会计官。他曾在多家私营和上市公司担任财务和会计职务，包括Arthur Anderson。Rodgers先生获得了圣克劳德州立大学的财务会计学士学位和明尼苏达大学卡尔森商学院的金融MBA学位。
- Richard Rodgers has served as a director since December 2014. In addition to his board seat with Rexahn, Mr. Rodgers currently serves on the Board of Directors of Ardelyx, Inc. and 3-V Biosciences, Inc. Mr. Rodgers was previously Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, an oncology-focused biopharmaceutical company that he co-founded, from March 2010 until August 2013. He served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience, which was subsequently acquired by Celgene. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, from 2004 until its acquisition by Eisai in January 2008. He has held finance and accounting positions at several private and public companies, including Arthur Anderson. Mr. Rodgers received a B.S. in Financial Accounting from St. Cloud State University and his MBA in Finance from the University of Minnesota, Carlson School of Business.
- Michael Raab
-
自2009年3月，Michael Raab担任Amicus Therapeutics, Inc.的总裁、首席执行官和董事。从2002年到2009年，他担任New Enterprise Associates, or NEA合伙人，一家风险投资公司，专门从事生物技术和制药行的医疗投资业。加入NEA之前，他在生物技术和制药行业担任商业和运营领导职务15年。他担任Genzyme Corporation治疗高级副总裁和Renal部门总经理，一家生物技术公司。他在Genzyme任职2年，在诊断产品和服务部门工作。加入Genzyme之前，他担任Repligen公司业务开发、销售和营销职务，一家生命科学公司和Bristol-Myers Squibb公司，一家生物制药公司。他拥有迪堡大学学士学位。
Michael Raab has served as a member of Tempest Therapeutics Inc's Board since June 2021, and served as Chairman of Tempest Therapeutics Inc's Board from June 2021 until February 2026 and as a member and Chairman of the board of directors of Tempest Therapeutics Inc's legacy company from December 2018 until June 2021. Mr. Raab has served as Ardelyx Inc.'s President and ChiefExecutive Officer since March 2009 and as a member of the board of directors since 2008. Before Ardelyx, Mr. Raab was a partner at New Enterprise Associates ("NEA"), where he focused on the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme's diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol Myers Corporation. Mr. Raab has been the lead independent director of Amicus Therapeutics, Inc. since 2004. Mr. Raab received his B.A. from DePauw University. - 自2009年3月，Michael Raab担任Amicus Therapeutics, Inc.的总裁、首席执行官和董事。从2002年到2009年，他担任New Enterprise Associates, or NEA合伙人，一家风险投资公司，专门从事生物技术和制药行的医疗投资业。加入NEA之前，他在生物技术和制药行业担任商业和运营领导职务15年。他担任Genzyme Corporation治疗高级副总裁和Renal部门总经理，一家生物技术公司。他在Genzyme任职2年，在诊断产品和服务部门工作。加入Genzyme之前，他担任Repligen公司业务开发、销售和营销职务，一家生命科学公司和Bristol-Myers Squibb公司，一家生物制药公司。他拥有迪堡大学学士学位。
- Michael Raab has served as a member of Tempest Therapeutics Inc's Board since June 2021, and served as Chairman of Tempest Therapeutics Inc's Board from June 2021 until February 2026 and as a member and Chairman of the board of directors of Tempest Therapeutics Inc's legacy company from December 2018 until June 2021. Mr. Raab has served as Ardelyx Inc.'s President and ChiefExecutive Officer since March 2009 and as a member of the board of directors since 2008. Before Ardelyx, Mr. Raab was a partner at New Enterprise Associates ("NEA"), where he focused on the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme's diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol Myers Corporation. Mr. Raab has been the lead independent director of Amicus Therapeutics, Inc. since 2004. Mr. Raab received his B.A. from DePauw University.
- David Mott
-
2009年3月以来，David Mott担任董事会董事，2014年3月以来，担任董事会主席。他于2008年9月加入NEA，担任公司普通合伙人，负责生物制药的投资。加入NEA之前，他是MedImmune总裁兼首席执行官，一家有限责任公司，阿斯利康的子公司，他担任阿斯利康的执行副总裁。他于1992年加入MedImmune，其职责不断增加，包括首席运营官、首席财务官、总裁和2000年担任首席执行官。他在2002年创立MedImmune公司，担任投资委员会主席，直到他离开MedImmune。加入MedImmune之前，他是Smith Barney, Harris Upham & Co.卫生保健投资银行集团副总裁，他专注于公共和私人股本和债务融资以及生物技术、医疗服务和医疗产品和设备公司的并购工作。他目前是TESARO主席，一家生物制药公司，Prosensa控股，一家生物制药公司，他担任Epizyme董事，一家生物制药公司。他拥有达特茅斯学院经济学与政治学士学位。
David Mott,has served on board of directors since March 2009 and as the chairperson of the board of directors since March 2014. Mr. Mott is currently a private investor through Mott Family Capital. Mr. Mott served as a general partner of New Enterprise Associates, or NEA, an investment firm focused on venture capital and growth equity investments from September 2008 to February 2020, where he led the healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc (NYSE: AZN), and served in numerous roles during his tenure, including from October 2000 to July 2008 as President and Chief Executive Officer, and previously as Chief Financial Officer, and as President and Chief Operating Officer. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca Plc from June 2007 to July 2008 following AstraZeneca Plc's acquisition of Medimmune Limited in June 2007. Prior to joining MedImmune Limited, Mr. Mott was a Vice President in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc. Mr. Mott received a B.A. in Economics and Government from Dartmouth College. Mr. Mott serves as the chairperson of the board of directors for Adaptimmune (Nasdaq: ADAP), and Mersana Therapeutics, Inc. (Nasdaq: MRSN), and serves on the board of directors of Novavax, Inc. (Nasdaq: NVAX). Additionally, he served as the chairperson of the board of directors of Imara Inc. from April 2016 to its acquisition by Enliven Therapeutics, Inc (Nasdaq: ELVN) in February 2023,and as the chairperson of the board of directors of Epizyme, Inc. (Nasdaq: EPZM) from December 2009 to its acquisition by Ipsen (Euronext: IPN; ADR: IPSEY) in August 2022. Mr. Mott also served as the chairperson of the board of directors of Tesaro, Inc. (Nasdaq: TSRO) and as a director of Nightstar Therapeutics plc (Nasdaq: IMRA). - 2009年3月以来，David Mott担任董事会董事，2014年3月以来，担任董事会主席。他于2008年9月加入NEA，担任公司普通合伙人，负责生物制药的投资。加入NEA之前，他是MedImmune总裁兼首席执行官，一家有限责任公司，阿斯利康的子公司，他担任阿斯利康的执行副总裁。他于1992年加入MedImmune，其职责不断增加，包括首席运营官、首席财务官、总裁和2000年担任首席执行官。他在2002年创立MedImmune公司，担任投资委员会主席，直到他离开MedImmune。加入MedImmune之前，他是Smith Barney, Harris Upham & Co.卫生保健投资银行集团副总裁，他专注于公共和私人股本和债务融资以及生物技术、医疗服务和医疗产品和设备公司的并购工作。他目前是TESARO主席，一家生物制药公司，Prosensa控股，一家生物制药公司，他担任Epizyme董事，一家生物制药公司。他拥有达特茅斯学院经济学与政治学士学位。
- David Mott,has served on board of directors since March 2009 and as the chairperson of the board of directors since March 2014. Mr. Mott is currently a private investor through Mott Family Capital. Mr. Mott served as a general partner of New Enterprise Associates, or NEA, an investment firm focused on venture capital and growth equity investments from September 2008 to February 2020, where he led the healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc (NYSE: AZN), and served in numerous roles during his tenure, including from October 2000 to July 2008 as President and Chief Executive Officer, and previously as Chief Financial Officer, and as President and Chief Operating Officer. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca Plc from June 2007 to July 2008 following AstraZeneca Plc's acquisition of Medimmune Limited in June 2007. Prior to joining MedImmune Limited, Mr. Mott was a Vice President in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc. Mr. Mott received a B.A. in Economics and Government from Dartmouth College. Mr. Mott serves as the chairperson of the board of directors for Adaptimmune (Nasdaq: ADAP), and Mersana Therapeutics, Inc. (Nasdaq: MRSN), and serves on the board of directors of Novavax, Inc. (Nasdaq: NVAX). Additionally, he served as the chairperson of the board of directors of Imara Inc. from April 2016 to its acquisition by Enliven Therapeutics, Inc (Nasdaq: ELVN) in February 2023,and as the chairperson of the board of directors of Epizyme, Inc. (Nasdaq: EPZM) from December 2009 to its acquisition by Ipsen (Euronext: IPN; ADR: IPSEY) in August 2022. Mr. Mott also served as the chairperson of the board of directors of Tesaro, Inc. (Nasdaq: TSRO) and as a director of Nightstar Therapeutics plc (Nasdaq: IMRA).
高管简历
中英对照 | 中文 | 英文- Laura Williams
Laura Williams已被我们的董事会提名为一级董事。自2020年11月以来，Williams博士一直担任生物制药公司Ardelyx, Inc.的全球治疗策略和患者宣传高级副总裁。在加入Ardelyx之前，她于2017年9月至2020年1月担任制药公司AMAG Pharmaceuticals, Inc.的高级副总裁兼临床开发和生物统计学主管。从2016年9月到2017年8月，Williams博士担任Myovant Sciences Ltd.（一家医疗保健公司）临床开发副总裁。从1998年到2016年7月，Williams博士在AbbVie，Inc.（正式雅培公司，一家生物制药公司）担任越来越重要的职务。威廉姆斯博士在密西西比州立大学获得学士学位，在爱荷华大学获得医学博士学位，在华盛顿大学获得流行病学硕士学位。
Laura Williams has been nominated by our board of directors to serve as a class I director. Since November 2020 Dr. Williams has served as the Senior Vice President, Global Therapeutic Strategies and Patient Advocacy for Ardelyx, Inc., a biopharmaceutical company. Prior to Ardelyx, she served as Senior Vice President and Head of Clinical Development and Biostatistics at AMAG Pharmaceuticals, Inc., a pharmaceutical company, from September 2017 until January 2020. From September 2016 to August 2017 Dr. Williams served as Vice President of Clinical Development at Myovant Sciences Ltd., a healthcare company. From 1998 to July 2016 Dr. Williams served in roles of increasing responsibility at AbbVie, Inc. formally Abbott Laboratories, a biopharmaceutical company. Dr. Williams received her B.S. from Mississippi State University, her M.D. from the University of Iowa and MPH in Epidemiology from the University of Washington.- Laura Williams已被我们的董事会提名为一级董事。自2020年11月以来，Williams博士一直担任生物制药公司Ardelyx, Inc.的全球治疗策略和患者宣传高级副总裁。在加入Ardelyx之前，她于2017年9月至2020年1月担任制药公司AMAG Pharmaceuticals, Inc.的高级副总裁兼临床开发和生物统计学主管。从2016年9月到2017年8月，Williams博士担任Myovant Sciences Ltd.（一家医疗保健公司）临床开发副总裁。从1998年到2016年7月，Williams博士在AbbVie，Inc.（正式雅培公司，一家生物制药公司）担任越来越重要的职务。威廉姆斯博士在密西西比州立大学获得学士学位，在爱荷华大学获得医学博士学位，在华盛顿大学获得流行病学硕士学位。
- Laura Williams has been nominated by our board of directors to serve as a class I director. Since November 2020 Dr. Williams has served as the Senior Vice President, Global Therapeutic Strategies and Patient Advocacy for Ardelyx, Inc., a biopharmaceutical company. Prior to Ardelyx, she served as Senior Vice President and Head of Clinical Development and Biostatistics at AMAG Pharmaceuticals, Inc., a pharmaceutical company, from September 2017 until January 2020. From September 2016 to August 2017 Dr. Williams served as Vice President of Clinical Development at Myovant Sciences Ltd., a healthcare company. From 1998 to July 2016 Dr. Williams served in roles of increasing responsibility at AbbVie, Inc. formally Abbott Laboratories, a biopharmaceutical company. Dr. Williams received her B.S. from Mississippi State University, her M.D. from the University of Iowa and MPH in Epidemiology from the University of Washington.
- Sue Hohenleitner
Sue Hohenleitner，在加入公司之前曾在上市的制药、生物技术和医疗技术公司强生（“J & J”）担任多个高级会计和财务职务。最近，自2022年8月以来，Hohenleitner女士担任强生（J & J）创新医学北美（NA）的副总裁兼首席财务官，该公司领导着360亿美元商业业务的财务战略。2019年4月至2022年8月，Hohenleitner女士担任J & J Innovation的财务副总裁。2018年5月至2019年4月，Hohenleitner女士担任强生财务、收购和剥离业务副总裁。2015年12月至2018年5月，Hohenleitner女士担任强生供应链交付财务副总裁。Hohenleitner女士是宾夕法尼亚州联邦的注册会计师和注册管理会计师。她在拉萨尔大学获得会计学学士学位，在维拉诺瓦获得工商管理硕士学位。
Sue Hohenleitner,worked at Johnson & Johnson ("J&J"), a publicly traded pharmaceutical, biotechnology, and medical technologies company, in various senior accounting and finance roles prior to joining the Company. Most recently, since August 2022, Ms. Hohenleitner served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a $36 billion commercial business, and from April 2019 to August 2022, Ms. Hohenleitner served as Vice President of Finance at J&J Innovation. From May 2018 to April 2019, Ms. Hohenleitner was Vice President of Finance, Acquisition and Divestiture Operations at J&J. From December 2015 to May 2018, Ms. Hohenleitner served as Vice President of Finance, J&J Supply Chain Deliver. Ms. Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova.- Sue Hohenleitner，在加入公司之前曾在上市的制药、生物技术和医疗技术公司强生（“J & J”）担任多个高级会计和财务职务。最近，自2022年8月以来，Hohenleitner女士担任强生（J & J）创新医学北美（NA）的副总裁兼首席财务官，该公司领导着360亿美元商业业务的财务战略。2019年4月至2022年8月，Hohenleitner女士担任J & J Innovation的财务副总裁。2018年5月至2019年4月，Hohenleitner女士担任强生财务、收购和剥离业务副总裁。2015年12月至2018年5月，Hohenleitner女士担任强生供应链交付财务副总裁。Hohenleitner女士是宾夕法尼亚州联邦的注册会计师和注册管理会计师。她在拉萨尔大学获得会计学学士学位，在维拉诺瓦获得工商管理硕士学位。
- Sue Hohenleitner,worked at Johnson & Johnson ("J&J"), a publicly traded pharmaceutical, biotechnology, and medical technologies company, in various senior accounting and finance roles prior to joining the Company. Most recently, since August 2022, Ms. Hohenleitner served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a $36 billion commercial business, and from April 2019 to August 2022, Ms. Hohenleitner served as Vice President of Finance at J&J Innovation. From May 2018 to April 2019, Ms. Hohenleitner was Vice President of Finance, Acquisition and Divestiture Operations at J&J. From December 2015 to May 2018, Ms. Hohenleitner served as Vice President of Finance, J&J Supply Chain Deliver. Ms. Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova.
- Mike Kelliher
Mike Kelliher，自2024年3月起担任企业发展和战略执行副总裁。2014年11月至2024年3月，Kelliher先生曾任职于Horizon Therapeutics（纳斯达克：NZNP），该公司于2023年10月被安进（纳斯达克：AMGN）收购。Kelliher先生最近于2022年1月至2024年3月在Horizon Therapeutics担任集团并购和业务发展副总裁，并于2016年4月至2021年12月担任业务发展副总裁。在任职Horizon Therapeutics之前，2009年至2014年，Kelliher先生在上市制药公司Elan Corporation（现为Perrigo Company）担任财务职务。Kelliher先生获得了科克大学学院（爱尔兰）的商业学士学位。
Mike Kelliher,has served as Executive Vice President, Corporate Development and Strategy since March 2024. From November 2014 to March 2024, Mr. Kelliher worked at Horizon Therapeutics (Nasdaq: NZNP), which was acquired in October 2023 by Amgen (Nasdaq: AMGN). Mr. Kelliher most recently served as Group Vice President, M&A and Business Development at Horizon Therapeutics from January 2022 to March 2024 and Vice President Business Development from April 2016 to December 2021. Prior to his time at Horizon Therapeutics, from 2009 to 2014, Mr. Kelliher held financial roles at Elan Corporation (now Perrigo Company), a public pharmaceutical company. Mr. Kelliher received a Bachelor of Commerce degree from the University College Cork (Ireland).- Mike Kelliher，自2024年3月起担任企业发展和战略执行副总裁。2014年11月至2024年3月，Kelliher先生曾任职于Horizon Therapeutics（纳斯达克：NZNP），该公司于2023年10月被安进（纳斯达克：AMGN）收购。Kelliher先生最近于2022年1月至2024年3月在Horizon Therapeutics担任集团并购和业务发展副总裁，并于2016年4月至2021年12月担任业务发展副总裁。在任职Horizon Therapeutics之前，2009年至2014年，Kelliher先生在上市制药公司Elan Corporation（现为Perrigo Company）担任财务职务。Kelliher先生获得了科克大学学院（爱尔兰）的商业学士学位。
- Mike Kelliher,has served as Executive Vice President, Corporate Development and Strategy since March 2024. From November 2014 to March 2024, Mr. Kelliher worked at Horizon Therapeutics (Nasdaq: NZNP), which was acquired in October 2023 by Amgen (Nasdaq: AMGN). Mr. Kelliher most recently served as Group Vice President, M&A and Business Development at Horizon Therapeutics from January 2022 to March 2024 and Vice President Business Development from April 2016 to December 2021. Prior to his time at Horizon Therapeutics, from 2009 to 2014, Mr. Kelliher held financial roles at Elan Corporation (now Perrigo Company), a public pharmaceutical company. Mr. Kelliher received a Bachelor of Commerce degree from the University College Cork (Ireland).
- Eric Foster
Eric Foster，自2024年8月起担任首席商务官。在此之前，Foster先生曾在安进（纳斯达克：AMGN）担任高级副总裁兼美国总经理，此前他于2023年10月收购了Horizon Therapeutics（纳斯达克：HZNP），并于2022年10月至2023年10月期间担任高级副总裁兼痛风和眼科业务部门总经理；于2021年5月至2022年10月期间担任集团副总裁兼痛风业务部门总经理。在加入Horizon Therapeutics之前，从2010年到2021年，福斯特先生在葛兰素史克公司（LSE/NYSE：GSK）的销售和营销组织中担任越来越多的职责，涉及各种免疫学和罕见病产品，包括担任免疫学营销副总裁、高级全球营销总监和现场销售副总裁。Foster先生的职业生涯始于强生（NYSE：JNJ）的销售和市场准入。Foster先生拥有乔治亚大学经济学文学士学位和奥本大学工商管理硕士学位。
Eric Foster,has served as Chief Commercial Officer since August 2024. Before that, Mr. Foster served as Senior Vice President and U.S. General Manager at Amgen (Nasdaq: AMGN), following the acquisition of Horizon Therapeutics (Nasdaq: HZNP) in October 2023 where he served as Senior Vice President and General Manager of the Gout and Ophthalmology Business Units from October 2022 until October 2023 and Group Vice President and General Manager of the Gout Business Unit from May 2021 until October 2022. Prior to his time at Horizon Therapeutics, from 2010 to 2021, Mr. Foster held roles of increasing responsibility within the sales and marketing organization at GlaxoSmithKline Plc (LSE/NYSE: GSK) across a variety of immunology and rare disease products, including serving as Vice President of Immunology Marketing, Senior Global Marketing Director and Field Sales Vice President. Mr. Foster began his career in sales and market access at Johnson & Johnson (NYSE: JNJ). Mr. Foster holds a Bachelor of Arts in Economics degree from the University of Georgia and a Master of Business Administration from Auburn University.- Eric Foster，自2024年8月起担任首席商务官。在此之前，Foster先生曾在安进（纳斯达克：AMGN）担任高级副总裁兼美国总经理，此前他于2023年10月收购了Horizon Therapeutics（纳斯达克：HZNP），并于2022年10月至2023年10月期间担任高级副总裁兼痛风和眼科业务部门总经理；于2021年5月至2022年10月期间担任集团副总裁兼痛风业务部门总经理。在加入Horizon Therapeutics之前，从2010年到2021年，福斯特先生在葛兰素史克公司（LSE/NYSE：GSK）的销售和营销组织中担任越来越多的职责，涉及各种免疫学和罕见病产品，包括担任免疫学营销副总裁、高级全球营销总监和现场销售副总裁。Foster先生的职业生涯始于强生（NYSE：JNJ）的销售和市场准入。Foster先生拥有乔治亚大学经济学文学士学位和奥本大学工商管理硕士学位。
- Eric Foster,has served as Chief Commercial Officer since August 2024. Before that, Mr. Foster served as Senior Vice President and U.S. General Manager at Amgen (Nasdaq: AMGN), following the acquisition of Horizon Therapeutics (Nasdaq: HZNP) in October 2023 where he served as Senior Vice President and General Manager of the Gout and Ophthalmology Business Units from October 2022 until October 2023 and Group Vice President and General Manager of the Gout Business Unit from May 2021 until October 2022. Prior to his time at Horizon Therapeutics, from 2010 to 2021, Mr. Foster held roles of increasing responsibility within the sales and marketing organization at GlaxoSmithKline Plc (LSE/NYSE: GSK) across a variety of immunology and rare disease products, including serving as Vice President of Immunology Marketing, Senior Global Marketing Director and Field Sales Vice President. Mr. Foster began his career in sales and market access at Johnson & Johnson (NYSE: JNJ). Mr. Foster holds a Bachelor of Arts in Economics degree from the University of Georgia and a Master of Business Administration from Auburn University.
- Michael Raab
自2009年3月，Michael Raab担任Amicus Therapeutics, Inc.的总裁、首席执行官和董事。从2002年到2009年，他担任New Enterprise Associates, or NEA合伙人，一家风险投资公司，专门从事生物技术和制药行的医疗投资业。加入NEA之前，他在生物技术和制药行业担任商业和运营领导职务15年。他担任Genzyme Corporation治疗高级副总裁和Renal部门总经理，一家生物技术公司。他在Genzyme任职2年，在诊断产品和服务部门工作。加入Genzyme之前，他担任Repligen公司业务开发、销售和营销职务，一家生命科学公司和Bristol-Myers Squibb公司，一家生物制药公司。他拥有迪堡大学学士学位。
Michael Raab has served as a member of Tempest Therapeutics Inc's Board since June 2021, and served as Chairman of Tempest Therapeutics Inc's Board from June 2021 until February 2026 and as a member and Chairman of the board of directors of Tempest Therapeutics Inc's legacy company from December 2018 until June 2021. Mr. Raab has served as Ardelyx Inc.'s President and Chief Executive Officer since March 2009 and as a member of the board of directors since 2008. Before Ardelyx, Mr. Raab was a partner at New Enterprise Associates ("NEA"), where he focused on the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme's diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol Myers Corporation. Mr. Raab has been the lead independent director of Amicus Therapeutics, Inc. since 2004. Mr. Raab received his B.A. from DePauw University.- 自2009年3月，Michael Raab担任Amicus Therapeutics, Inc.的总裁、首席执行官和董事。从2002年到2009年，他担任New Enterprise Associates, or NEA合伙人，一家风险投资公司，专门从事生物技术和制药行的医疗投资业。加入NEA之前，他在生物技术和制药行业担任商业和运营领导职务15年。他担任Genzyme Corporation治疗高级副总裁和Renal部门总经理，一家生物技术公司。他在Genzyme任职2年，在诊断产品和服务部门工作。加入Genzyme之前，他担任Repligen公司业务开发、销售和营销职务，一家生命科学公司和Bristol-Myers Squibb公司，一家生物制药公司。他拥有迪堡大学学士学位。
- Michael Raab has served as a member of Tempest Therapeutics Inc's Board since June 2021, and served as Chairman of Tempest Therapeutics Inc's Board from June 2021 until February 2026 and as a member and Chairman of the board of directors of Tempest Therapeutics Inc's legacy company from December 2018 until June 2021. Mr. Raab has served as Ardelyx Inc.'s President and Chief Executive Officer since March 2009 and as a member of the board of directors since 2008. Before Ardelyx, Mr. Raab was a partner at New Enterprise Associates ("NEA"), where he focused on the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries, including serving as Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme's diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol Myers Corporation. Mr. Raab has been the lead independent director of Amicus Therapeutics, Inc. since 2004. Mr. Raab received his B.A. from DePauw University.